関連する実験動画
Updated: Jun 10, 2026

09:03
Manufacture and Drug Delivery Applications of Silk Nanoparticles
Published on: October 8, 2016
pH感受性ナノバルブによるメソポラスシリカナノ粒子からの自律的なin vitro抗癌薬の放出
1Division of NanoMedicine, Department of Medicine, University of California, Los Angeles, California 90095, USA.
Journal of the American Chemical Society
|August 20, 2010
まとめ
新型メソポラスシリカナノ粒子 (MSNP) は,標的型薬物投与のためにβ-サイクロデクストリン (β-CD) ナノバルブを使用しています. これらのナノバルブは細胞の条件に反応し,がん細胞内のドクソルビシンなどの治療薬の制御された放出を可能にします.
科学分野:
- ナノテクノロジー ナノテクノロジー
- マテリアルサイエンス 材料科学
- バイオメディカルエンジニアリング
背景:
- メソポラスシリカナノ粒子 (MSNP) は,薬物の投与を制御するための効果的な固体支柱です.
- MSNPの表面機能化は,貨物の放出のためのナノ孔開口の制御を可能にします.
- 以前のMSNPシステムは,ナノバルブを使用してアビオティック条件下で貨物を運びました.
研究 の 目的:
- MSNPの薬物投与システムを生物学的用途に適応させる.
- 細胞内条件に反応するナノバルブでMSNPを開発する.
- ベータ・サイクロデクストリン (ベータ-CD) ナノバルブが,がん細胞における薬物の放出を誘発することを調査する.
主な方法:
- ベータ-サイクロデクストリン (ベータ-CD) ナノバルブで機能した設計MSNP.
- THP-1およびKB-31細胞系におけるエンドソーマ酸性化に対するナノバルブ反応のテスト.
- KB-31細胞核にドクソルビシンを効率的に放出するために,MSNP表面を最適化しました.
主要な成果:
- エンドソーム酸性化に反応したベータ-CDナノバルブの開口が実証された.
- 癌細胞内のMSNPからドクソルビシンが制御的に放出される.
- 核薬の迅速な投与のための最適化されたMSNP表面機能.
結論:
- pH反応性β-CDナノバルブを用いた新しいMSNP薬物投与システムを開発しました.
- 癌細胞の核に薬物を投与するシステムの有効性を検証した.
- 合わせたナノバルブを持つMSNPは,標的がん治療のための有望なプラットフォームを提供します.
関連する概念動画
Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
